Abstract 211P
Background
The ATLAS trial compared axitinib (AXI) vs placebo in patients (pts) with locoregional renal cell carcinoma at risk of recurrence after nephrectomy. ATLAS was stopped due to futility at a pre-planned interim analysis. A subgroup analysis was performed to describe differences between Asian vs Non-Asian pts and different Asian groups by geography in baseline characteristics and safety.
Methods
The exploratory subgroup analysis population included 363 pts randomized to receive AXI and 361 randomized to placebo. The primary endpoint was disease-free survival (DFS).
Results
DFS had the largest treatment effect in highest risk pts for Asian and Non-Asian pts: Hazard ratio = 0.731 (Asians) vs. 0.755 (Non-Asians). A similar trend was noted for Fuhrman Grade 3-4. Additional key results from the analysis are presented in the table.
Table: 211P Summary of key findings
Axitinib N = 363 | Placebo N = 361 | |||
---|---|---|---|---|
Asian N = 262 | Non- Asian N = 101 | Asian N = 264 | Non- Asian N = 97 | |
Key Pts Characteristics | ||||
Pts in Highest Risk Group, % | 51.9 | 72.3 | 51.5 | 66.0 |
Median time since diagnosis, wk | 8.7 | 10.3 | 8.6 | 10.0 |
Drug Treatment Differences | ||||
Completed 3y Treatment, % | 31.5 | 15.0 | 31.1 | 15.6 |
Median Treatment Duration, mo | 25.3 | 15.6 | 27.0 | 22.9 |
Median Daily Dose, mg | 6.6 | 8.6 | 9.9 | 10.0 |
Pts Safety Experience | ||||
Frequency of Dose Reduction, % | 68.5 | 50.0 | 11.7 | 7.3 |
AE Leading to Dose Reduction, % | 58.8 | 46.0 | 7.6 | 10.4 |
AE Leading to Discontinuation, % | 27.3 | 15.0 | 12.1 | 10.4 |
AE=adverse events Asian pts on AXI had higher frequencies of proteinuria, hypothyroidism, and nasopharyngitis and lower frequencies of fatigue and asthenia compared to Non-Asian pts on AXI. Within major Asian groups, proteinuria, hypothyroidism, nasopharyngitis and hypertension were more common in Japanese > Korean > Chinese pts.
Conclusions
DFS did not vary based on ethnicity. Asian pts had a lower median daily dose, and more frequent dose reduction vs non-Asian pts. More Asian pts had AEs leading to dose reductions of AXI and study withdrawals vs non-Asian pts. There were notable differences in AEs between Asian and Non-Asian pts and between Japanese, Korean and Chinese pts.
Clinical trial identification
NCT01599754.
Editorial acknowledgement
The study is sponsored by Pfizer. Medical writing support was provided by Charles Cheng, MS, of Engage Scientific Solutions, and funded by Pfizer.
Legal entity responsible for the study
This study was sponsored by Pfizer Inc and SFJ Pharmaceuticals.
Funding
This study was sponsored by Pfizer Inc and SFJ Pharmaceuticals.
Disclosure
C.F. Ng: Advisory / Consultancy, Speaker Bureau / Expert testimony: Boston Scientific; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Astellas; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Ferring; Speaker Bureau / Expert testimony: Amgen; Research grant / Funding (institution): Olympus. T.G. Kwon: Research grant / Funding (institution): Kyungpook National University Chilgok Hospital. M. Eto: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): ONO; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Bayer. S.I. Seo: Honoraria (self): Ipsen; Honoraria (self): Pfizer; Research grant / Funding (self): Alvogen. B. Rosbrook: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. E. Grande: Honoraria (self), Research grant / Funding (self): Pfizer; Honoraria (self): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (self): IPSEN; Honoraria (self), Research grant / Funding (self): Roche; Honoraria (self): Eisai; Honoraria (self): Eusa Pharma; Honoraria (self): MSD; Honoraria (self): Sanofi-Genzyme; Honoraria (self): Adacap; Honoraria (self): Novartis; Honoraria (self): Pierre Fabre; Honoraria (self), Research grant / Funding (self): Lexicon; Honoraria (self): Celgene; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): MTEM/Threshold. M. Gross-Goupil: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Research grant / Funding (self): Ipsen; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Amgen. D.I. Quinn: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Bayer; Advisory / Consultancy: Novartis; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Merck; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Genentech; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
304P - Survival outcomes and survival predictors in recurrent and metastatic head and neck squamous cell cancer (R/M-HNSCC) patients treated with chemotherapy (CT) plus cetuximab as first-line therapy in a real-world study
Presenter: Filipa Pontes
Session: Poster display session
Resources:
Abstract
305P - A retrospective study to evaluate patient characteristics for recurrent head and neck cancer after definitive treatment
Presenter: Tetsuro Wakasugi
Session: Poster display session
Resources:
Abstract
306P - Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck
Presenter: Lin Gui
Session: Poster display session
Resources:
Abstract
307P - Lacrimal gland tumours: Clinical and epidemiological patterns in the United States
Presenter: Mahmoud KhalafAllah
Session: Poster display session
Resources:
Abstract
308P - Dental prophylaxis and 5-fluorouracil related oral mucositis in head and neck cancer patients: A population-based cohort study
Presenter: Yi-Fang Huang
Session: Poster display session
Resources:
Abstract
309P - Evaluation of a pharmacist-led opioid de-escalation (PLODE) program after chemoradiotherapy completion in head and neck cancer patients
Presenter: Ai Horinouchi
Session: Poster display session
Resources:
Abstract
310P - Laser and PDT for the oral leukoplakia
Presenter: Sadykov Rasul
Session: Poster display session
Resources:
Abstract
311P - Incidence of thyroid carcinoma in the Philippines: A retrospective study from a tertiary university hospital
Presenter: Priscilla Caguioa
Session: Poster display session
Resources:
Abstract
312P - Oral health disparities among privileged and underprivileged tribes of south India - A study on precancerous oral lesions prevalence
Presenter: Shanavas Palliyal
Session: Poster display session
Resources:
Abstract
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract